For most of medical history, we treated cancer by cutting, burning, or poisoning it. Immunotherapy takes a completely different approach — it reprograms the body’s own defenses to do the work. And it’s changing everything.
The immune system already fights cancer — cancer just fights back
Your immune system is constantly surveilling your body for abnormal cells — and it finds and destroys many potential cancers before they ever become a problem. Cancer cells that survive have, by definition, found ways to evade this surveillance. They display surface proteins that signal ‘don’t attack me’ to immune cells. They create a suppressive microenvironment that disarms T cells before they can act. They essentially hijack the very system designed to destroy them.
Immunotherapy works by breaking through these evasion strategies — either by removing the brakes that cancer places on immune cells, by genetically engineering immune cells to be more effective hunters, or by training the immune system to recognize cancer-specific targets more aggressively.
Immune checkpoint inhibitors: taking the brakes off
The first major class of immunotherapy to transform cancer treatment was immune checkpoint inhibitors. These drugs block proteins like PD-1, PD-L1, and CTLA-4 — molecular ‘off switches’ that cancer cells exploit to suppress T cell activity. By blocking these checkpoints, the drugs allow T cells to attack tumors they would otherwise ignore.
The results in some cancers have been remarkable. In advanced melanoma — historically one of the most lethal diagnoses — checkpoint inhibitor combinations have produced long-term survival in a subset of patients who would previously have had months to live. According to Frontiers in Pharmacology (2025), of the 28 FDA approvals announced in the first half of 2025, 12 were immunotherapy drugs — reflecting how central this approach has become to modern oncology.
CAR-T cell therapy: building a custom cancer hunter
CAR-T cell therapy takes the concept further. T cells are removed from a patient’s blood, genetically engineered in the lab to express chimeric antigen receptors (CARs) — synthetic proteins that recognize specific markers on cancer cells — then infused back into the patient. These modified cells are, in effect, custom-built cancer hunters, programmed to seek and destroy tumors bearing their target antigen.
CAR-T therapy has produced extraordinary results in blood cancers. Two of the first patients ever treated with CAR-T cell therapy for leukemia — treated at the University of Pennsylvania — remained in complete remission 12 years later, as reported in Nature. Presented at ASCO 2025, 12 phase I clinical studies showed emerging results for CAR-T in solid tumors — historically much more resistant to this approach — with new strategies being tested for glioblastoma, where median overall survival had previously ranged from only 6 to 9 months.
🧬 Next-generation CAR-T: Armored T cells — next-generation CAR-T cells engineered to express their own cytokines — are showing improved ability to persist and function inside the hostile tumor microenvironment. Research presented at AACR IO 2025/2026 highlighted IL-18, IL-12, and IL-15 armored variants, with modular designs incorporating switchable signaling domains and payload delivery systems.
mRNA cancer vaccines: the next frontier
The mRNA vaccine technology that became globally known through COVID-19 is now being applied to cancer. Unlike infectious disease vaccines, cancer mRNA vaccines are personalized — they are designed based on the specific mutation profile of each patient’s tumor, training the immune system to recognize and attack those unique cancer fingerprints. Early results from Moderna and Merck’s personalized mRNA vaccine combined with pembrolizumab (a checkpoint inhibitor) showed a 49% reduction in the risk of recurrence or death in stage II/III melanoma patients in a phase IIb trial.
According to analysis published by Definitive Healthcare (2025), mRNA cancer vaccines represent one of the three key innovations to watch in 2026, alongside radiopharmaceuticals and liquid biopsies — each promising to further shift the balance in cancer treatment.
📊 2025 immunotherapy by numbers: 12 of 28 FDA cancer approvals in first half of 2025 were immunotherapy drugs. CAR-T first patients: still in remission at 12 years. mRNA vaccine trial: 49% reduction in melanoma recurrence risk. Hundreds of active clinical trials in cancer immunotherapy globally.